Stem Cell Transplantation Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Stem Cell Transplantation Market 

5.1. COVID-19 Landscape: Stem Cell Transplantation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Stem Cell Transplantation Market, By Transplant Type

8.1. Stem Cell Transplantation Market, by Transplant Type

8.1.1. Allogeneic Transplant

8.1.1.1. Market Revenue and Forecast

8.1.2. Autologous Transplant

8.1.2.1. Market Revenue and Forecast

8.1.3. Syngeneic Transplant

8.1.3.1. Market Revenue and Forecast 

Chapter 9. Global Stem Cell Transplantation Market, By Stem Cell Source

9.1. Stem Cell Transplantation Market, by Stem Cell Source

9.1.1. Peripheral Blood Stem Cell Transplant

9.1.1.1. Market Revenue and Forecast

9.1.2. Bone Marrow Transplant

9.1.2.1. Market Revenue and Forecast

9.1.3. Cord Blood Transplant

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Stem Cell Transplantation Market, By March 

10.1. Stem Cell Transplantation Market, by Indication/Disease

10.1.1. Leukemia

10.1.1.1. Market Revenue and Forecast

10.1.2. Lymphoproliferative Disorders

10.1.2.1. Market Revenue and Forecast

10.1.3. Non-malignant Disorders

10.1.3.1. Market Revenue and Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Stem Cell Transplantation Market, By April 

11.1. Stem Cell Transplantation Market, by End-User

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Transplant/Cellular Therapy Centers

11.1.2.1. Market Revenue and Forecast

11.1.3. Specialty Clinics

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Stem Cell Transplantation Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Transplant Type

12.1.2. Market Revenue and Forecast, by Stem Cell Source

12.1.3. Market Revenue and Forecast, by Indication/Disease

12.1.4. Market Revenue and Forecast, by End-User

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Transplant Type

12.1.5.2. Market Revenue and Forecast, by Stem Cell Source

12.1.5.3. Market Revenue and Forecast, by Indication/Disease

12.1.5.4. Market Revenue and Forecast, by End-User

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Transplant Type

12.1.6.2. Market Revenue and Forecast, by Stem Cell Source

12.1.6.3. Market Revenue and Forecast, by Indication/Disease

12.1.6.4. Market Revenue and Forecast, by End-User

12.2. Europe

12.2.1. Market Revenue and Forecast, by Transplant Type

12.2.2. Market Revenue and Forecast, by Stem Cell Source

12.2.3. Market Revenue and Forecast, by Indication/Disease

12.2.4. Market Revenue and Forecast, by End-User

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Transplant Type

12.2.5.2. Market Revenue and Forecast, by Stem Cell Source

12.2.5.3. Market Revenue and Forecast, by Indication/Disease

12.2.5.4. Market Revenue and Forecast, by End-User

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Transplant Type

12.2.6.2. Market Revenue and Forecast, by Stem Cell Source

12.2.6.3. Market Revenue and Forecast, by Indication/Disease

12.2.6.4. Market Revenue and Forecast, by End-User

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Transplant Type

12.2.7.2. Market Revenue and Forecast, by Stem Cell Source

12.2.7.3. Market Revenue and Forecast, by Indication/Disease

12.2.7.4. Market Revenue and Forecast, by End-User

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Transplant Type

12.2.8.2. Market Revenue and Forecast, by Stem Cell Source

12.2.8.3. Market Revenue and Forecast, by Indication/Disease

12.2.8.4. Market Revenue and Forecast, by End-User

12.3. APAC

12.3.1. Market Revenue and Forecast, by Transplant Type

12.3.2. Market Revenue and Forecast, by Stem Cell Source

12.3.3. Market Revenue and Forecast, by Indication/Disease

12.3.4. Market Revenue and Forecast, by End-User

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Transplant Type

12.3.5.2. Market Revenue and Forecast, by Stem Cell Source

12.3.5.3. Market Revenue and Forecast, by Indication/Disease

12.3.5.4. Market Revenue and Forecast, by End-User

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Transplant Type

12.3.6.2. Market Revenue and Forecast, by Stem Cell Source

12.3.6.3. Market Revenue and Forecast, by Indication/Disease

12.3.6.4. Market Revenue and Forecast, by End-User

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Transplant Type

12.3.7.2. Market Revenue and Forecast, by Stem Cell Source

12.3.7.3. Market Revenue and Forecast, by Indication/Disease

12.3.7.4. Market Revenue and Forecast, by End-User

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Transplant Type

12.3.8.2. Market Revenue and Forecast, by Stem Cell Source

12.3.8.3. Market Revenue and Forecast, by Indication/Disease

12.3.8.4. Market Revenue and Forecast, by End-User

12.4. MEA

12.4.1. Market Revenue and Forecast, by Transplant Type

12.4.2. Market Revenue and Forecast, by Stem Cell Source

12.4.3. Market Revenue and Forecast, by Indication/Disease

12.4.4. Market Revenue and Forecast, by End-User

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Transplant Type

12.4.5.2. Market Revenue and Forecast, by Stem Cell Source

12.4.5.3. Market Revenue and Forecast, by Indication/Disease

12.4.5.4. Market Revenue and Forecast, by End-User

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Transplant Type

12.4.6.2. Market Revenue and Forecast, by Stem Cell Source

12.4.6.3. Market Revenue and Forecast, by Indication/Disease

12.4.6.4. Market Revenue and Forecast, by End-User

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Transplant Type

12.4.7.2. Market Revenue and Forecast, by Stem Cell Source

12.4.7.3. Market Revenue and Forecast, by Indication/Disease

12.4.7.4. Market Revenue and Forecast, by End-User

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Transplant Type

12.4.8.2. Market Revenue and Forecast, by Stem Cell Source

12.4.8.3. Market Revenue and Forecast, by Indication/Disease

12.4.8.4. Market Revenue and Forecast, by End-User

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Transplant Type

12.5.2. Market Revenue and Forecast, by Stem Cell Source

12.5.3. Market Revenue and Forecast, by Indication/Disease

12.5.4. Market Revenue and Forecast, by End-User

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Transplant Type

12.5.5.2. Market Revenue and Forecast, by Stem Cell Source

12.5.5.3. Market Revenue and Forecast, by Indication/Disease

12.5.5.4. Market Revenue and Forecast, by End-User

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Transplant Type

12.5.6.2. Market Revenue and Forecast, by Stem Cell Source

12.5.6.3. Market Revenue and Forecast, by Indication/Disease

12.5.6.4. Market Revenue and Forecast, by End-User

Chapter 13. Company Profiles

13.1. Lonza Group Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Novartis AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck KGaA

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Cynata Therapeutics Ltd.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Pluristem Therapeutics Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. ThermoGenesis Holdings, Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Escape Therapeutics, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Regen BioPharma, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. CSG-BIO Company, Inc. (CellSave)

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. CBR Systems, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms